The Result of a Successful Partnership

Thursday evening, August 29, the residence served as a beautiful setting for a reception to celebrate the Euro- pean approval of Bavarian Nordic’s new IMVANEX smallpox vaccine.
The vaccine, called IMVAMUNE® in the U.S., has been developed through a suc- cessful ten-year partnership be- tween Bavarian Nordic and the U.S. Government supported by the Danish Embassy.

Paul Chaplin, Bavarian Nordic’s Infectious Disease Divi- sion President expressed his gratefulness, “IMVANEX is the first smallpox vaccine ap- proved in all European Union countries. We thank the Am- bassador for helping us cele-
brate our company’s first product approval.”

Ambassador Taksøe-Jensen, who hosted the celebration, also ex- pressed his delight at Bavarian Nordic’s achievement in his wel- coming speech; “The Danish Embassy is delighted to host this celebration of a milestone for one our key business partners. It is truly an excellent example of how a strategic relationship like ours can add great value to all parties involved”

Several high-ranking persons within the field of bio- preparedness and bio defence were present to celebrate this triumph for Bavarian Nordic.

Everyone conveyed their sincerest congratulations to Bavarian Nordic for achieving this landmark approval.

[box]IMVANEX® is the name of a new smallpox vaccine developed by Bavarian Nordic.

The vaccine stands out from other smallpox vaccines as it does not proliferate and replicate in the body and therefore does not generate post-vaccine complications. Furthermore, the vaccine is faster at generating an immune response than traditional vaccines.

IMVANEX is being stockpiled by the U.S. and other governments for bioterrorism preparedness.[/box]